You just read:

Further Study of Combination of Eisai's Lenvatinib and Merck's Pembrolizumab in Previously Treated Patients with Metastatic Endometrial Cancer Supported by Interim Analysis of Ongoing Phase 1b/2 Trial

News provided by

Eisai Inc.

Jun 03, 2017, 14:24 ET